Loïc Chartier

1.3k total citations
22 papers, 495 citations indexed

About

Loïc Chartier is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Loïc Chartier has authored 22 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Loïc Chartier's work include Lymphoma Diagnosis and Treatment (16 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Loïc Chartier is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Loïc Chartier collaborates with scholars based in France, United States and Italy. Loïc Chartier's co-authors include Michel Meignan, Olivier Casasnovas, Anne‐Ségolène Cottereau, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Jehan Dupuis, Corinne Haïoun, Stefano Luminari and Annibale Versari and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Loïc Chartier

18 papers receiving 494 citations

Peers

Countries citing papers authored by Loïc Chartier

Since Specialization

Citations

This map shows the geographic impact of Loïc Chartier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loïc Chartier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loïc Chartier more than expected).

Fields of papers citing papers by Loïc Chartier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loïc Chartier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loïc Chartier. The network helps show where Loïc Chartier may publish in the future.

Co-authorship network of co-authors of Loïc Chartier

This figure shows the co-authorship network connecting the top 25 collaborators of Loïc Chartier. A scholar is included among the top collaborators of Loïc Chartier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loïc Chartier. Loïc Chartier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis 2025 ·Blood Advances ·(unknown), Gildas Bertho, (unknown), Loïc Chartier, (unknown), Fabrice Jardin, Hervé Ghesquières, Cédric Rossi, Franck Morschhauser, Corinne Haïoun, Vincent Ribrag, Pierre Feugier, (unknown), Lucie Obéric, Philippe Gaulard, Nicolas Giraud, Younès Bennani, Catherine Thieblemont, Véronique Baud	0
2	Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials 2025 ·Blood Cancer Journal ·(unknown), (unknown), Fanny Cherblanc, (unknown), (unknown), (unknown), Fontanet Bijou, Pierre Sesques, (unknown), Luc‐Matthieu Fornecker, (unknown), Sylvain Carras, Loïc Chartier, Aurélien Belot, Lucie Obéric, Fabrice Jardin, Benoît Tessoulin	0
3	Case presentation and management of Lyme disease patients: a 9-year retrospective analysis in France 2024 ·Frontiers in Medicine ·Émeline Perthame, Loïc Chartier, (unknown), Marie Varloud, Elisabeth Ferquel, Valérie Choumet	3
4	Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance 2024 ·Blood ·Camille Laurent, Preeti Trisal, Bruno Tesson, Sahil Seth, (unknown), Sandrine Roulland, (unknown), Nathalie Van Acker, (unknown), Loïc Chartier, Arnaud Guillé, (unknown), (unknown), Sarah Huet, Anita K. Gandhi, Franck Morschhauser, Luc Xerri	4
5	Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients 2023 ·Hematological Oncology ·Camille Laurent, Preeti Trisal, Bruno Tesson, (unknown), (unknown), Loïc Chartier, Matthew P. Stokes, Christine Huang, Sarah Huet, Franck Morschhauser, Anita K. Gandhi, Luc Xerri	1
6	Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups) 2023 ·Hematological Oncology ·(unknown), (unknown), (unknown), Loïc Chartier, (unknown), Eliana B Gómez, Bertrand Nadel, Luc Xerri, Franck Morschhauser, Salim Kanoun, Cédric Rossi	0
7	A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration 2023 ·Blood ·Marita Ziepert, Bettina Altmann, Viola Poeschel, (unknown), Loïc Chartier, Nicolas Ketterer, Christian Récher, Olivier Fitoussi, Gerhard Held, Olivier Casasnovas, Corinne Haïoun, Nicolas Mounier, Hervé Tilly, Franck Morschhauser, Andreas Rosenwald, German Ott, Thierry Jo Molina, Georg Lenz, Catherine Thiéblemont, Norbert Schmitz	0
8	RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXES 2023 ·Hematological Oncology ·Catherine Thiéblemont, Loïc Chartier, Laëtitia Vercellino, Jean‐François Deux, Olivier Casasnovas, (unknown), Véronique Baud, Hervé Tilly, Anne‐Ségolène Cottereau	1
9	Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment 2023 ·British Journal of Haematology ·Aurélien Belot, Vincent Camus, (unknown), (unknown), Loïc Chartier, Pascale Cony‐Makhoul, Hervé Tilly, (unknown)	1
10	Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells 2022 ·Haematologica ·Jean Galtier, Laëtitia Vercellino, Loïc Chartier, Philippe Olivier, (unknown), Charles Mesguich, Roberta Di Blasi, Amandine Durand, (unknown), François‐Xavier Gros, Isabelle Madelaine, Véronique Meignin, Miryam Mebarki, Marie‐Thérèse Rubio, Pierre Feugier, Olivier Casasnovas, Michel Meignan, Catherine Thiéblemont	19
11	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT 2021 ·Cancers ·Anne‐Ségolène Cottereau, Michel Meignan, Christophe Nioche, Jérôme Clerc, Loïc Chartier, Laëtitia Vercellino, Olivier Casasnovas, Catherine Thiéblemont, Irène Buvat	24
12	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL. 2021 ·Journal of Clinical Oncology ·Catherine Thiéblemont, Bettina Altmann, Olivier Casasnovas, (unknown), Franck Morschhauser, Lucie Obéric, Viola Poeschel, Olivier Fitoussi, Loïc Renaud, Georg Lenz, Nicolas Mounier, Andreas Rosenwald, German Ott, Thierry Jo Molina, Marie Parrens, Loïc Chartier, Marita Ziepert, Hervé Tilly, Norbert Schmitz	1
13	Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT† 2020 ·Annals of Oncology ·Anne‐Ségolène Cottereau, Michel Meignan, Christophe Nioche, (unknown), Jérôme Clerc, Loïc Chartier, Laëtitia Vercellino, Olivier Casasnovas, Catherine Thiéblemont, Irène Buvat	105
14	OUTCOME AND TREATMENT OF RELAPSING EARLY PET NEGATIVE PATIENTS INCLUDED IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA 2019 ·Hematological Oncology ·Anne‐Claire Gac, Loïc Chartier, T. Girinsky, Manuel Gotti, Julien Lazarovici, Igor Aurer, Pellegrino Musto, Ghandi Damaj, Massimo Federico, Catherine Fortpied, John Raemaekers, Michel Meignan, Martin Hutchings, (unknown), Marc André, Oumédaly Reman	4
15	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 2018 ·Blood ·Anne‐Ségolène Cottereau, Annibale Versari, Stefano Luminari, Jehan Dupuis, Loïc Chartier, Olivier Casasnovas, Alina Berriolo-Riedinger, Massimo Menga, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Gilles Salles, Judith Trotman, Michel Meignan	52
16	PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS 2017 ·Hematological Oncology ·Anne‐Ségolène Cottereau, Annibale Versari, Jehan Dupuis, Loïc Chartier, Massimo Menga, Olivier Casasnovas, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Julien Dubreuil, Massimo Federico, Gilles Salles, Stefano Luminari, Judith Trotman, Michel Meignan	1
17	Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma 2016 ·Journal of Nuclear Medicine ·Anne‐Ségolène Cottereau, Sébastien Hapdey, Loïc Chartier, Romain Modzelewski, Olivier Casasnovas, Emmanuel Itti, Hervé Tilly, (unknown), Michel Meignan, Stéphanie Becker	47
18	Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 2016 ·Journal of Clinical Oncology ·Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, Loïc Chartier, Jehan Dupuis, Sami Boussetta, Ilaria Grassi, Olivier Casasnovas, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Julien Dubreuil, Massimo Federico, Gilles Salles, Stefano Luminari, Judith Trotman	220
19	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies 2015 ·Blood ·Michel Meignan, Annibale Versari, Anne‐Ségolène Cottereau, Loïc Chartier, Jehan Dupuis, Sami Boussetta, Ilaria Grassi, Olivier Casasnovas, Corinne Haïoun, Hervé Tilly, Massimo Federico, Gilles Salles, Stefano Luminari, Judith Trotman	1
20	Clinical Trials and E-Health: Impact of New Information Technology Applied to Clinical Trials (Including Source Data-Medical Records) and to Human and Drug Research 2010 ·Therapies ·Jéhan‐Michel Béhier, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Loïc Chartier, (unknown), (unknown), E. Leutenegger, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact